How to develop a successful cancer drug – molecules to medicines or targets to treatments?
- 1 March 2005
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (5) , 676-682
- https://doi.org/10.1016/j.ejca.2004.12.024
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung CancerJAMA, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Molecular footprints of human lung cancer progressionCancer Science, 2004
- Proliferation of cancer cells despite CDK2 inhibitionCancer Cell, 2003
- Molecular Genetics of Lung CancerAnnual Review of Medicine, 2003
- Complexities in the development of cyclin-dependent kinase inhibitor drugsTrends in Molecular Medicine, 2002
- Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studiesBMJ, 2000
- CDK inhibitors: positive and negative regulators of G1-phase progressionGenes & Development, 1999
- The regulation of E2F by pRB-family proteinsGenes & Development, 1998
- Polyglutamation of methotrexate. Is methotrexate a prodrug?Journal of Clinical Investigation, 1985